首页 > 最新文献

Annals of Family Medicine最新文献

英文 中文
The Shoeshine Stand and the Renaissance of Primary Care. 擦鞋摊和初级保健的文艺复兴。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-07-01 DOI: 10.1370/afm.3137
John J Frey

Over the past century, family physicians have moved from small independently owned practices, many of them solo, to being employed by large hospital systems, corporate entities, or health systems. Today, almost three-quarters of all physicians are employed and the highest percentage of employed physicians are family physicians.This essay contrasts the elements of independent practice with employed practice as part of what has been lost in the past half century, but what might be regained if physicians demanded more autonomy and control over their practices.

在过去的一个世纪里,家庭医生从独立开业的小诊所(其中许多是个体诊所)转变为受雇于大型医院系统、公司实体或医疗系统。今天,几乎四分之三的医生都是受雇于人,而受雇医生中比例最高的是家庭医生。这篇文章对比了独立执业和受雇执业的要素,作为过去半个世纪中失去的东西的一部分,但如果医生要求对自己的执业有更多的自主权和控制权,可能会重新获得什么。
{"title":"The Shoeshine Stand and the Renaissance of Primary Care.","authors":"John J Frey","doi":"10.1370/afm.3137","DOIUrl":"10.1370/afm.3137","url":null,"abstract":"<p><p>Over the past century, family physicians have moved from small independently owned practices, many of them solo, to being employed by large hospital systems, corporate entities, or health systems. Today, almost three-quarters of all physicians are employed and the highest percentage of employed physicians are family physicians.This essay contrasts the elements of independent practice with employed practice as part of what has been lost in the past half century, but what might be regained if physicians demanded more autonomy and control over their practices.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 4","pages":"347-349"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fifty Years of Connection: Characterizing the Social Network of a Primary Care Research Organization. 五十年的联系:基层医疗研究机构社会网络的特征。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-07-01 DOI: 10.1370/afm.3126
Sarah C Gebauer, Jacqueline K Kueper, Danielle Varda, Jennifer A Lawlor, John M Westfall, Judith Belle Brown

Purpose: This study marks the 50th anniversary of NAPCRG (formerly the North American Primary Care Research Group) by examining social connections among members.

Methods: This descriptive social network analysis was conducted via the Program to Analyze, Record, and Track Networks to Enhance Relationships (PARTNER) survey tool.

Results: Responses from 906 participants resulted in 1,721 individuals with 5,196 partner relationships. Most relationships (60%) were characterized as having an integrated level of collaboration. Many relationships led to a research paper (58%) or a grant (34%).

Conclusions: This social network analysis of NAPCRG members' relationships described over 5,000 relationships, many producing publications, grants, and perceived advancements in primary care.

目的:本研究通过考察成员之间的社会关系来纪念 NAPCRG(前身为北美初级保健研究小组)成立 50 周年:这项描述性社会网络分析是通过 "分析、记录和跟踪网络以加强关系计划"(PARTNER)调查工具进行的:906 名参与者的回复结果显示,1721 人拥有 5196 个伴侣关系。大多数关系(60%)被描述为具有综合合作水平。许多关系导致了一篇研究论文(58%)或一项基金(34%):对 NAPCRG 成员关系的社会网络分析描述了 5,000 多条关系,其中许多关系产生了论文、基金,并使人们认识到初级保健的进步。
{"title":"Fifty Years of Connection: Characterizing the Social Network of a Primary Care Research Organization.","authors":"Sarah C Gebauer, Jacqueline K Kueper, Danielle Varda, Jennifer A Lawlor, John M Westfall, Judith Belle Brown","doi":"10.1370/afm.3126","DOIUrl":"10.1370/afm.3126","url":null,"abstract":"<p><strong>Purpose: </strong>This study marks the 50th anniversary of NAPCRG (formerly the North American Primary Care Research Group) by examining social connections among members.</p><p><strong>Methods: </strong>This descriptive social network analysis was conducted via the Program to Analyze, Record, and Track Networks to Enhance Relationships (PARTNER) survey tool.</p><p><strong>Results: </strong>Responses from 906 participants resulted in 1,721 individuals with 5,196 partner relationships. Most relationships (60%) were characterized as having an integrated level of collaboration. Many relationships led to a research paper (58%) or a grant (34%).</p><p><strong>Conclusions: </strong>This social network analysis of NAPCRG members' relationships described over 5,000 relationships, many producing publications, grants, and perceived advancements in primary care.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 4","pages":"333-335"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis. 用于轻度/中度严重 COVID-19 的 Nirmatrelvir/Ritonavir 方案:带有 Meta 分析和试验序列分析的快速回顾。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-07-01 DOI: 10.1370/afm.3120
George N Okoli, Nicole Askin, Rasheda Rabbani

Background: The efficacy, effectiveness, and safety of the approved nirmatrelvir/ritonavir regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains unclear.

Methods: We systematically identified randomized controlled trials (RCTs) and real-world studies (RWS; observational studies) of the efficacy/effectiveness and/or safety of the approved nirmatrelvir/ritonavir regimen for COVID-19. We pooled appropriate data (adjusted estimates for RWS) using an inverse variance, random-effects model. We calculated statistical heterogeneity using the I 2 statistic. Results are presented as relative risk (RR) with associated 95% CI. We further assessed risk of bias/study quality and conducted trial sequential analysis of the evidence from RCTs.

Results: We included 4 RCTs (4,070 persons) and 16 RWS (1,925,047 persons) of adults (aged ≥18 years). One and 3 RCTs were of low and unclear risk of bias, respectively. The RWS were of good quality. Nirmatrelvir/ritonavir significantly decreased COVID-19 hospitalization compared with placebo/no treatment (RR = 0.17; 95% CI, 0.10-0.31; I 2 = 77.2%; 2 RCTs, 3,542 persons), but there was no significant difference for decrease of worsening severity (RR = 0.82; 95% CI, 0.66-1.01; I 2 = 47.5%; 3 RCTs, 1,824 persons), viral clearance (RR = 1.19; 95% CI, 0.93-1.51; I 2 = 82%; 2 RCTs, 528 persons), adverse events (RR = 1.41; 95% CI, 0.92-2.14; I 2 = 70.6%; 4 RCTs, 4,070 persons), serious adverse events (RR = 0.82; 95% CI, 0.41-1.62; I 2 = 0%; 3 RCTs, 3,806 persons), and all-cause mortality (RR = 0.27; 95% CI, 0.04-1.70; I 2 = 49.9%; 3 RCTs, 3,806 persons), although trial sequential analysis suggested that the current total sample sizes for these outcomes were not large enough for conclusions to be drawn. Real-world studies also showed significantly decreased COVID-19 hospitalization (RR = 0.48; 95% CI, 0.37-0.60; I 2 = 95.0%; 11 RWS, 1,421,398 persons) and all-cause mortality (RR = 0.24; 95% CI, 0.14-0.34; I 2 = 65%; 7 RWS, 286,131 persons) for nirmatrelvir/ritonavir compared with no treatment.

Conclusions: Nirmatrelvir/ritonavir appears to be promising for preventing hospitalization and potentially decreasing all-cause mortality for persons with mild/moderately severe COVID-19, but the evidence is weak. More studies are needed.

背景已获批准的尼尔马特韦/利托那韦方案治疗实验室确诊的轻度/中度重度 COVID-19 的疗效、有效性和安全性仍不明确:我们系统地确定了已获批准的奈瑞韦/利托那韦方案治疗 COVID-19 的疗效/有效性和/或安全性的随机对照试验 (RCT) 和真实世界研究 (RWS;观察性研究)。我们采用反方差随机效应模型汇集了适当的数据(RWS 的调整估计值)。我们使用 I 2 统计量计算统计异质性。结果以相对风险 (RR) 及相关的 95% CI 表示。我们进一步评估了偏倚风险/研究质量,并对来自 RCT 的证据进行了试验序列分析:我们纳入了针对成人(年龄≥18 岁)的 4 项 RCT(4,070 人)和 16 项 RWS(1,925,047 人)。分别有 1 项和 3 项研究性试验存在低偏倚风险和不明确偏倚风险。RWS质量良好。与安慰剂/不治疗相比,Nirmatrelvir/利托那韦能显著降低COVID-19的住院率(RR = 0.17; 95% CI, 0.10-0.31; I 2 = 77.2%; 2项研究,3,542人),但在降低恶化严重程度方面没有显著差异(RR = 0.82;95% CI,0.66-1.01;I 2 = 47.5%;3 项 RCT,1 824 人)、病毒清除率(RR = 1.19;95% CI,0.93-1.51;I 2 = 82%;2 项 RCT,528 人)、不良事件(RR = 1.41;95% CI,0.92-2.14;I 2 = 70.6%;4 项 RCT,4070 人)、严重不良事件(RR = 0.82;95% CI,0.41-1.62;I 2 = 0%;3 项 RCT,3806 人)和全因死亡率(RR = 0.27;95% CI,0.04-1.70;I 2 = 49.9%;3 项 RCT,3806 人),但试验顺序分析表明,目前这些结果的总样本量还不足以得出结论。真实世界研究还显示,与不治疗相比,尼马瑞韦/利托那韦的COVID-19住院率(RR=0.48;95% CI,0.37-0.60;I 2=95.0%;11个RWS,1,421,398人)和全因死亡率(RR=0.24;95% CI,0.14-0.34;I 2=65%;7个RWS,286,131人)显著降低:结论:对于轻度/中度重度 COVID-19 患者,尼马瑞韦/利托那韦似乎有望预防住院并降低全因死亡率,但证据尚不充分。还需要更多的研究。
{"title":"Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis.","authors":"George N Okoli, Nicole Askin, Rasheda Rabbani","doi":"10.1370/afm.3120","DOIUrl":"10.1370/afm.3120","url":null,"abstract":"<p><strong>Background: </strong>The efficacy, effectiveness, and safety of the approved nirmatrelvir/ritonavir regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains unclear.</p><p><strong>Methods: </strong>We systematically identified randomized controlled trials (RCTs) and real-world studies (RWS; observational studies) of the efficacy/effectiveness and/or safety of the approved nirmatrelvir/ritonavir regimen for COVID-19. We pooled appropriate data (adjusted estimates for RWS) using an inverse variance, random-effects model. We calculated statistical heterogeneity using the <i>I</i> <sup>2</sup> statistic. Results are presented as relative risk (RR) with associated 95% CI. We further assessed risk of bias/study quality and conducted trial sequential analysis of the evidence from RCTs.</p><p><strong>Results: </strong>We included 4 RCTs (4,070 persons) and 16 RWS (1,925,047 persons) of adults (aged ≥18 years). One and 3 RCTs were of low and unclear risk of bias, respectively. The RWS were of good quality. Nirmatrelvir/ritonavir significantly decreased COVID-19 hospitalization compared with placebo/no treatment (RR = 0.17; 95% CI, 0.10-0.31; <i>I</i> <sup>2</sup> = 77.2%; 2 RCTs, 3,542 persons), but there was no significant difference for decrease of worsening severity (RR = 0.82; 95% CI, 0.66-1.01; <i>I</i> <sup>2</sup> = 47.5%; 3 RCTs, 1,824 persons), viral clearance (RR = 1.19; 95% CI, 0.93-1.51; <i>I</i> <sup>2</sup> = 82%; 2 RCTs, 528 persons), adverse events (RR = 1.41; 95% CI, 0.92-2.14; <i>I</i> <sup>2</sup> = 70.6%; 4 RCTs, 4,070 persons), serious adverse events (RR = 0.82; 95% CI, 0.41-1.62; <i>I</i> <sup>2</sup> = 0%; 3 RCTs, 3,806 persons), and all-cause mortality (RR = 0.27; 95% CI, 0.04-1.70; <i>I</i> <sup>2</sup> = 49.9%; 3 RCTs, 3,806 persons), although trial sequential analysis suggested that the current total sample sizes for these outcomes were not large enough for conclusions to be drawn. Real-world studies also showed significantly decreased COVID-19 hospitalization (RR = 0.48; 95% CI, 0.37-0.60; <i>I</i> <sup>2</sup> = 95.0%; 11 RWS, 1,421,398 persons) and all-cause mortality (RR = 0.24; 95% CI, 0.14-0.34; <i>I</i> <sup>2</sup> = 65%; 7 RWS, 286,131 persons) for nirmatrelvir/ritonavir compared with no treatment.</p><p><strong>Conclusions: </strong>Nirmatrelvir/ritonavir appears to be promising for preventing hospitalization and potentially decreasing all-cause mortality for persons with mild/moderately severe COVID-19, but the evidence is weak. More studies are needed.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 4","pages":"336-346"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practice Transformation in the Transforming Clinical Practice Initiative and Emergency Department Use. 临床实践转型计划中的实践转型与急诊室的使用。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-07-01 DOI: 10.1370/afm.3119
Lori Timmins, Suzanne Felt-Lisk, Wenjia Zhu, Angela Merrill, Jelena Zurovac, Shawan Johnson, Damian Everhart, Robert Flemming

To provide insight on how ambulatory care practices can reduce emergency department (ED) visits, we studied changes in Medicare ED visits for primary and specialty care practices in the Transforming Clinical Practice Initiative. We compared practices that transformed more vs less during the 6-year period ending in 2021 (3,773 practices). Using data from a practice transformation assessment tool completed at multiple intervals, we found improvement in the transformation score was associated with reduced ED visits by 6% and 4% for primary and specialty care practices, respectively, 3 to 4 years after first assessment. Transformation in 5 of 8 domains contributed to reduced ED visits.

为了深入了解非住院医疗机构如何才能减少急诊室(ED)就诊人次,我们研究了 "临床实践转型计划 "中初级和专科医疗机构的医疗保险 ED 就诊人次的变化。我们比较了在截至 2021 年的 6 年期间转型较多的医疗机构和转型较少的医疗机构(3773 家医疗机构)。利用在多个时间间隔内完成的实践转型评估工具提供的数据,我们发现转型得分的提高与首次评估后 3 到 4 年内初级和专科医疗实践的急诊就诊率分别降低 6% 和 4% 有关。在 8 个领域中,有 5 个领域的转型有助于减少急诊就诊人次。
{"title":"Practice Transformation in the Transforming Clinical Practice Initiative and Emergency Department Use.","authors":"Lori Timmins, Suzanne Felt-Lisk, Wenjia Zhu, Angela Merrill, Jelena Zurovac, Shawan Johnson, Damian Everhart, Robert Flemming","doi":"10.1370/afm.3119","DOIUrl":"10.1370/afm.3119","url":null,"abstract":"<p><p>To provide insight on how ambulatory care practices can reduce emergency department (ED) visits, we studied changes in Medicare ED visits for primary and specialty care practices in the Transforming Clinical Practice Initiative. We compared practices that transformed more vs less during the 6-year period ending in 2021 (3,773 practices). Using data from a practice transformation assessment tool completed at multiple intervals, we found improvement in the transformation score was associated with reduced ED visits by 6% and 4% for primary and specialty care practices, respectively, 3 to 4 years after first assessment. Transformation in 5 of 8 domains contributed to reduced ED visits.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 4","pages":"325-328"},"PeriodicalIF":4.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Prediabetes Overdiagnosed? No: A Clinician's Perspective. 糖尿病前期诊断过度吗?不是:临床医生的视角。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 DOI: 10.1370/afm.3101
Jonathan G Gabison
{"title":"Is Prediabetes Overdiagnosed? No: A Clinician's Perspective.","authors":"Jonathan G Gabison","doi":"10.1370/afm.3101","DOIUrl":"10.1370/afm.3101","url":null,"abstract":"","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":" ","pages":"251-253"},"PeriodicalIF":4.4,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Primary Care in the Social Isolation and Loneliness Epidemic. 初级保健在社会隔离和孤独流行病中的作用。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 DOI: 10.1370/afm.3102
Rebecca A Mullen, Sebastian T Tong, Hillary D Lum, Kari A Stephens, Alex H Krist

The United States is facing a social isolation and loneliness crisis. In response, the US Surgeon General issued an advisory in May 2023 recommending actions that health care, community programs, and social services can take to collaboratively improve social connection. Primary care has a critical role to play in implementing the Surgeon General's recommendations. We present social isolation and loneliness as medical issues and highlight next steps for the primary care sector to combat this epidemic.Annals Early Access article.

美国正面临着社会隔离和孤独危机。为此,美国卫生总监于 2023 年 5 月发布了一份咨询报告,建议医疗保健、社区计划和社会服务部门采取行动,共同改善社会联系。在落实卫生总监建议的过程中,基础医疗发挥着至关重要的作用。我们将社会隔离和孤独视为医疗问题,并强调了初级医疗部门为应对这一流行病而采取的下一步措施。
{"title":"The Role of Primary Care in the Social Isolation and Loneliness Epidemic.","authors":"Rebecca A Mullen, Sebastian T Tong, Hillary D Lum, Kari A Stephens, Alex H Krist","doi":"10.1370/afm.3102","DOIUrl":"10.1370/afm.3102","url":null,"abstract":"<p><p>The United States is facing a social isolation and loneliness crisis. In response, the US Surgeon General issued an advisory in May 2023 recommending actions that health care, community programs, and social services can take to collaboratively improve social connection. Primary care has a critical role to play in implementing the Surgeon General's recommendations. We present social isolation and loneliness as medical issues and highlight next steps for the primary care sector to combat this epidemic.<i>Annals</i> Early Access article.</p>","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":" ","pages":"244-246"},"PeriodicalIF":4.4,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Prediabetes Overdiagnosed? Yes: A Patient-Epidemiologist's Experience. 糖尿病前期是否被过度诊断?是的:患者-流行病学家的经验。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 DOI: 10.1370/afm.3093
Rani Marx
{"title":"Is Prediabetes Overdiagnosed? Yes: A Patient-Epidemiologist's Experience.","authors":"Rani Marx","doi":"10.1370/afm.3093","DOIUrl":"10.1370/afm.3093","url":null,"abstract":"","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":" ","pages":"247-250"},"PeriodicalIF":4.4,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Servant Leadership into the Fabric of NAPCRG. 将仆人式领导融入 NAPCRG 的组织结构。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 DOI: 10.1370/afm.3124
Vivian R Ramsden, Tom Vansaghi
{"title":"Integrating Servant Leadership into the Fabric of NAPCRG.","authors":"Vivian R Ramsden, Tom Vansaghi","doi":"10.1370/afm.3124","DOIUrl":"10.1370/afm.3124","url":null,"abstract":"","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 3","pages":"262-263"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilizing Medical Assistants to Manage Patient Portal Messages. 利用医疗助理管理患者门户网站信息。
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 DOI: 10.1370/afm.3105
Jennifer N Lee, Laura Kurash, Max Yang, Joseph Teel
{"title":"Utilizing Medical Assistants to Manage Patient Portal Messages.","authors":"Jennifer N Lee, Laura Kurash, Max Yang, Joseph Teel","doi":"10.1370/afm.3105","DOIUrl":"10.1370/afm.3105","url":null,"abstract":"","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 3","pages":"261"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Wall of Evidence for Continuity of Care: How Many More Bricks Do We Need? 持续护理的证据墙:我们还需要多少块砖?
IF 4.4 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-01 DOI: 10.1370/afm.3116
Otto R Maarsingh
{"title":"The Wall of Evidence for Continuity of Care: How Many More Bricks Do We Need?","authors":"Otto R Maarsingh","doi":"10.1370/afm.3116","DOIUrl":"10.1370/afm.3116","url":null,"abstract":"","PeriodicalId":50973,"journal":{"name":"Annals of Family Medicine","volume":"22 3","pages":"184-186"},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Family Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1